Treatment Patterns and Transfusion Outcomes Among Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in Routine Clinical Practice in the United States (US)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
real-world data, myelodysplastic syndromes, blood transfusion, clinical outcome
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要